Biomedical subjects

S Sevinc

Publications and source records attributed to S Sevinc.

5 recordsLinked to original sources

PubMed2006

[Functional results of surgical treatment of bronchiectasis in a developing country].

BACKGROUND: The prevalence of bronchiectasis has decreased significantly over recent decades in developed countries. However, resection for bronchiectasis still plays an important part in thoracic surgery practice in developing countries such as Turkey. This study was designed to evaluate the outcomes of surgical treatment for bronchiectasis, particularly in aspects related to the effects on functional well-being. PATIENTS AND METHOD: From January 1995 through December 2003, operations for bronchiectasis were performed in 81 patients. Demographic features, type of resection, and operative morbidity and mortality were evaluated. The outcomes related to overall "social" or nonpulmonary functional status were classified and compared according to a scale constructed to assess patients' well-being preoperatively and at the 6th postoperative month. RESULTS: The mean age was 24.4 years and 47 patients (58%) were male. Surgical treatment was lobectomy in 37 (45%), pneumonectomy in 10 (12%), segmentectomy in 13 (16%), and lobectomy plus segmentectomy in 22 (27%) of the operations. Complete resection of disease was achieved in 69 patients (85%). There was no operative mortality. The rate of morbidity was 18.3%. Improvement to a functional status of excellent was observed in 81.7% and improvement to a status of good was seen in 12.7% of patients; 5.6% experienced no change. The results of complete resection were significantly better than those of incomplete resection (P=.0015). CONCLUSION: Functional results of surgical treatment for bronchiectasis in this series suggest that the outcomes are favorable and promising, particularly in selected patients with sufficient pulmonary reserves and localized disease who are suitable for complete resection.

Adolescent↗

PubMed2001

Endostatin inhibits angiogenesis by stabilization of newly formed endothelial tubes.

Endostatin decreased vascular endothelial growth factor (VEGF)-induced formation of endothelial tubes and microvessels sprouting from aortic rings and blocked their network. After cessation of treatment, the survival time of endostatin plus VEGF-treated tubes was approximately doubled in comparison to VEGF alone. Endostatin antibody blocked VEGF-induced endothelial tube formation and disrupted existing tubes. Endostatin immunostaining was localized between endothelium and basement membrane and in inter-endothelial junctions of new, but not of quiescent, blood vessels. In tumors grown in SCID mice, endostatin immunostaining was stronger accompanying blood vessel maturation and was significantly prominent in vessels of tumor marginal zone where angiogenesis is highly active. These data indicate a new antiangiogenic action of endostatin stabilizing and maturating endothelial tubes of newly formed blood vessels. Thus, strategies accelerating vascular stabilization and maturation could be promising in tumor therapy.

Angiogenesis Inhibitors↗

PubMed2001

Atypically located pericardial cysts.

Pericardial cysts are generally recognized when they present in a cardiophrenic angle, but may not be suspected when they occur elsewhere in the thorax. To highlight the unusual localisations of pericardial cysts, we represent two patients with cysts of which one was adjacent to the left pulmonary hilum and the other was located in the subpulmonary region. The clinicians should take into consideration this entity in the differential diagnosis of cystic lesions of the mediastinum.

Adult↗

PubMed2000

Alternative splicing, expression, and genomic structure of the 3' region of the gene encoding the sarcolemmal-associated proteins (SLAPs) defines a novel class of coiled-coil tail-anchored membrane proteins.

The sarcolemmal associated proteins (SLAPs) are encoded by multiple mRNAs that are presumably generated by alternative splicing mechanisms. The amino acid sequence of the SLAP1 isoform exhibited 76% identity with TOP(AP), a topographically graded antigen of the chick visual system. The regions of coiled-coil structure including an 11-heptad acidic amphipathic alpha-helical segment was conserved with a major divergence in sequence noted in the hydrophobic C termini predicted to be transmembrane domains in the two polypeptides. The genomic organization of the 3' region of the SLAP gene indicated that SLAP1 and TOP(AP) are generated by alternative splicing mechanisms, which are conserved among mammalian and avian species. SLAP1/TOP(AP) were encoded by 11 exons distributed over a minimum of 35 kilobase pairs of continuous DNA; 9 of the exons were constitutively expressed, and 2 were alternatively spliced. The exons range in size from 60 to 321 base pairs, and the predicted functional domains within the polypeptides were encompassed by single exons. The introns vary from 0.2 to 10 kilobase pairs and conform to consensus dinucleotide splicing signals. Reverse transcriptase-polymerase chain reaction studies demonstrated that alternative exons (IV and X) of SLAP were expressed in a tissue-specific fashion and developmentally regulated. The alternatively spliced exon X, which encodes the putative transmembrane anchor in TOP(AP), and a constitutively expressed exon XI, which encodes the putative transmembrane domain in SLAP, were found to target these polypeptides to membrane structures. The presence and conservation of termination codons in exons X and XI render expression of the two SLAP1/TOP(AP) transmembrane domains mutually exclusive. These data reveal that TOP(AP) and SLAP are alternatively spliced products of a single gene that encodes a unique class of tail-anchored membrane proteins.

3' Untranslated Regions↗

PubMedDate not supplied

The expression of angiopoietins and their receptor Tie-2 in human prostate carcinoma.

BACKGROUND: Angiopoietin-1 and angiopoietin-2 are antagonist angiogenic factors acting via the same receptor Tie-2. Their role in prostate carcinoma (PCa) is not known. MATERIAL AND METHODS: Using immunohistochemistry, localization of angiopoietin-1, angiopoietin-2 and their receptor Tie-2 was studied in normal human prostate and PCa. RESULTS: Few epithelial cells of normal prostate expressed angiopoietin-1 and Tie-2 but not angiopoietin-2. Normal prostate blood vessels were negative. In PCa, intraductal grown tumor cells showed angiopoietin-1 but not angiopoietin-2. Blood vessels close to the ducts and some apical tumor cells expressed angiopoietin-1 and Tie-2. In glandular PCa, most of the tumor and intraglandular stromal cells were positive for both angiopoietin-1 and angiopoietin-2. Angiopoietin-1 and angiopoietin-2 were also found in tumor capillaries. Additionally, angiopoietin-2 was expressed in smooth muscle cells of intratumoral blood vessels which also exhibited Tie-2. CONCLUSIONS: The results presented indicate a role of angiopoietin-Tie-2 system, particularly of angiopoietin-2 in the vascularization of PCa.

Adenocarcinoma↗